Comment on Afshar-Oromieh et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions

@article{Reske2013CommentOA,
  title={Comment on Afshar-Oromieh et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions},
  author={S. Reske and Gordon Winter and B. Baur and H. Machulla and T. Kull},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2013},
  volume={40},
  pages={969 - 970}
}
Dear Sir, It was with particular interest that we read the article by Afshar-Oromieh et al. [1]. The authors developed a novel 68Ga-labelled prostate-specific membrane antigen (PSMA)-binding small molecule, combining the well-known urea-based inhibitory motif glutamate-urea-lysine [2] with the lipophilic N,N′-bis[2-hydroxy-5-(carboxyethyl)-benzyl]ethylenediamine-N,N′-diacetic acid (HBED-CC) chelator for 68Ga [3]. The authors reasoned that the lipophilicity of HBED-CC might improve binding to… Expand
[Ga-68-PSMA PET/CT for prostate cancer].
...
1
2
...

References

SHOWING 1-6 OF 6 REFERENCES
First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer
Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.
68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.